Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO.

Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study, published ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with ...

Analysis: Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses ... that PMB-treated mice exhibited reduced infiltration of interferon-gamma (IFN-γ ...

Immunotherapy has revolutionized the management of cancer, including liver malignancies ... This effect is associated with increased infiltration and activation of cytotoxic T lymphocytes and ...

He was enrolled in a clinical trial for immunotherapy — a type of treatment that uses the patient's own immune system to fight cancer — that began in October 2013. Lung cancer poses a larger ...

Driving Innovation of Cancer Immunotherapy BOT has demonstrated ... enhancing T-cell infiltration and antitumor responses in preclinical models. These findings provide a strong rationale for ...

ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...

ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...